Literature DB >> 11906285

Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer.

Pedro M Matias1, Maria Arménia Carrondo, Ricardo Coelho, Monica Thomaz, Xiao-Yan Zhao, Anja Wegg, Kerstin Crusius, Ursula Egner, Peter Donner.   

Abstract

The crystal structure of a mutant androgen receptor (AR) ligand-binding domain (LBD) in complex with the agonist 9alpha-fluorocortisol has been determined at 1.95 A resolution. This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al. Nature Med. 2000, 6, 703-6). The three-dimensional structure of the AR(ccr) LBD complexed with 9alpha-fluorocortisol shows the typical conformation of an agonist-bound nuclear receptor in which helix 12 is precisely positioned as a "lid" for the ligand-binding pocket. Binding of 9alpha-fluorocortisol to the AR(ccr) involves favorable hydrogen bond patterns on the C17 and C21 substituents of the ligand due to the mutations at 701 and 877 in the AR(ccr). Our studies provide the first structural explanation for the glucocorticoid activation of AR(ccr), which is important for the development of new therapeutic treatments for androgen-independent prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11906285     DOI: 10.1021/jm011072j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

Review 1.  Chemistry and structural biology of androgen receptor.

Authors:  Wenqing Gao; Casey E Bohl; James T Dalton
Journal:  Chem Rev       Date:  2005-09       Impact factor: 60.622

2.  Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer.

Authors:  Dong Jin Hwang; Jun Yang; Huiping Xu; Igor M Rakov; Michael L Mohler; James T Dalton; Duane D Miller
Journal:  Bioorg Med Chem       Date:  2006-07-07       Impact factor: 3.641

3.  C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition.

Authors:  A Cannistraci; G Federici; A Addario; A L Di Pace; L Grassi; G Muto; D Collura; M Signore; L De Salvo; S Sentinelli; G Simone; M Costantini; S Nanni; A Farsetti; V Coppola; R De Maria; D Bonci
Journal:  Oncogene       Date:  2017-02-13       Impact factor: 9.867

Review 4.  The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside.

Authors:  Jieping Hu; Qingke Chen
Journal:  Int Urol Nephrol       Date:  2016-12-16       Impact factor: 2.370

5.  The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions.

Authors:  Fred Schaufele; Xavier Carbonell; Martin Guerbadot; Sabine Borngraeber; Mark S Chapman; Aye Aye K Ma; Jeffrey N Miner; Marc I Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-01       Impact factor: 11.205

6.  Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity.

Authors:  Karine Pereira de Jésus-Tran; Pierre-Luc Côté; Line Cantin; Jonathan Blanchet; Fernand Labrie; Rock Breton
Journal:  Protein Sci       Date:  2006-05       Impact factor: 6.725

7.  Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.

Authors:  Dennis J van de Wijngaart; Michel Molier; Scott J Lusher; Remko Hersmus; Guido Jenster; Jan Trapman; Hendrikus J Dubbink
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

8.  Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells.

Authors:  Silke Kaulfuss; Michal Grzmil; Bernhard Hemmerlein; Paul Thelen; Stefan Schweyer; Jürgen Neesen; Lukas Bubendorf; Andrew G Glass; Hubertus Jarry; Bernd Auber; Peter Burfeind
Journal:  Mol Endocrinol       Date:  2008-05-01

Review 9.  Enzalutamide for the treatment of prostate cancer.

Authors:  Sumanta K Pal; Cy A Stein; Oliver Sartor
Journal:  Expert Opin Pharmacother       Date:  2013-02-27       Impact factor: 3.889

10.  A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.

Authors:  Yiu-Keung Lau; Manpreet K Chadha; Alan Litwin; Donald L Trump
Journal:  J Hematol Oncol       Date:  2008-11-05       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.